Phase II Study of Irinotecan in Combination with Capecitabine on a 3-Weekly Schedule as First-Line Chemotherapy for Patients with Metastatic or Locally Advanced Colorectal Cancer

Authors

  • Antonieta Salud Hospital Universitario Arnau de Vilanova, Lleida, Spain
  • Vicente Alonso Hospital Universitario Miguel Servet, Zaragoza, Spain
  • Pilar Escudero Hospital Clínico Lozano Blesa, Zaragoza, Spain
  • Miguel Burillo Hospital San Jorge, Huesca, Spain
  • Cristina Martín Hospital Espíritu Santo, Barcelona Spain
  • Fernando Rivera Hospital Marqués de Valdecilla, Santander, Spain
  • Alfonso Yubero Hospital Obispo Polanco, Teruel, Spain
  • Carlos García-Girón Hospital General Yagüe, Burgos, Spain
  • Alberto Muñoz Hospital Universitario de Cruces, Barakaldo, Spain

DOI:

https://doi.org/10.6000/1927-7229.2013.02.03.4

Keywords:

CPT-11, Capecitabine, Irinotecan, XELIRI regimen, Colorectal cancer.

Abstract

 Background: Capecitabine has demonstrated non inferiority efficacy and improved safety compared with 5-fluorouracil (5-FU)/leucovorin (LV) in metastatic colorectal cancer (mCRC) without the inconvenience of an infusional therapy. The aim of the present study was to evaluate the efficacy and safety of capecitabine plus irinotecan (CPT-11) given every 3 weeks (XELIRI regimen) as first-line treatment in locally advanced (LA) or mCRC, in order to improve patient tolerability and quality of life. Patients and methods: Patients with LA or mCRC received CPT-11 225 mg/m2(180 mg/m2 if > 65 years old) on day 1 and capecitabine 1000 mg/m2 (750 mg/m2 if > 65 years old) twice daily on days 2-15 every 3 week. Primary endpoints were objective response rate (ORR) and toxicity of the chemotherapeutic regimen. Secondary endpoints of overall survival (OS), progression-free survival (PFS), response duration and quality of life were also evaluated. Results: Ninety-one patients were included. In an intention-to-treat analysis, complete response was achieved in 3 patients and partial response in 27, for an ORR of 33%. The disease control rate (ORR + stable disease) was 72.5%. Median time to progression and OS were 9.3 and 17.1 months respectively. Grade 3/4 neutropenia and diarrhea were the most commonly reported adverse vents. Conclusion: The XELIRI regimen given every 3 weeks, as first-line therapy of LA or mCRC was effective and well tolerated, including elderly patients. Severe gastrointestinal toxicities and hematological events were manageable.

References

American cancer Society. Caner facts and Figures 2009. Atlanta, GA. Available at: http://www.cancer.org/downloads/ STT/500809web.pdf

Midgley R, Kerr D. Colorectal cancer. Lancet 1999; 353: 391-99. http://dx.doi.org/10.1016/S0140-6736(98)07127-X

Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75. http://dx.doi.org/10.1200/JCO.2004.03.104

Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.

Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665-75. http://dx.doi.org/10.1200/JCO.2003.08.008

Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer 1998; 34: 1509-13. http://dx.doi.org/10.1016/S0959-8049(98)00226-3

Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Capecitabine, alone and in combination, in the management of patients with colorectal cancer. Drugs 2008; 68: 949-61. http://dx.doi.org/10.2165/00003495-200868070-00005

Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.

Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-18. http://dx.doi.org/10.1016/S0140-6736(98)02309-5

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-47. http://dx.doi.org/10.1016/S0140-6736(00)02034-1

Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, et al. Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100: 279-87. http://dx.doi.org/10.1002/cncr.11910

Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, et al. A randomized phase II trial of capecitabine and two different schedules if irinotecan in first- line treatment in metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 2005; 16: 282-88. http://dx.doi.org/10.1093/annonc/mdi047

Cartwright T, Lopez T, Vukelja SJ, Encarnacion C, Boehm KA, Asmar L. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer 2005; 5: 50-56. http://dx.doi.org/10.3816/CCC.2005.n.016

Patt YZ, Lee FC, Liebmann JE, Diamandidis D, Eckhardt SG, Javle M, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol 2007; 30: 350-57. http://dx.doi.org/10.1097/COC.0b013e31804b40bb

Garcia-Alfonso P, Muñoz-Martin A, Méndez-Ureña M, Quiben-Pereira R, Gonzalez-Flores E, Perez-Manga G. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer 2009; 101: 1039-43. http://dx.doi.org/10.1038/sj.bjc.6605261

Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-86. http://dx.doi.org/10.1200/JCO.2007.11.3357

Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19: 920-26. http://dx.doi.org/10.1093/annonc/mdm544

Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-42. http://dx.doi.org/10.1016/S0140-6736(07)61086-1

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16. http://dx.doi.org/10.1093/jnci/92.3.205

Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-47. http://dx.doi.org/10.1016/S0959-8049(99)00150-1

Van Cutsem E, Khöne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17. http://dx.doi.org/10.1056/NEJMoa0805019

Choi CK, Chan RT, Tung SY, Lui L, Siu S, Au GK, et al. Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6. Clin Oncol (R Coll Radiol) 2008; 20: 168-75. http://dx.doi.org/10.1016/j.clon.2007.11.008

Skof E, Rebersek M, Hlebanja Z, Ocvirk J. Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 2009; 9: 120. http://dx.doi.org/10.1186/1471-2407-9-120

Cartwright T, McCollum D, Boehm KA. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. Am J Clin Oncol 2010; 33: 307-13. http://dx.doi.org/10.1097/COC.0b013e3181d27361

Punt C, Koopman M. Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer. J Clin Oncol 2008; 26: 1907. http://dx.doi.org/10.1200/JCO.2007.15.9640

Díaz-Rubio E, Tabernero J, Gómez-España A, Massutí B, Sastre J, Chaves M, et al. Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007; 25: 4224-30. http://dx.doi.org/10.1200/JCO.2006.09.8467

Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-12. http://dx.doi.org/10.1200/JCO.2007.14.9898

Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer 2004; 4: 46-50. http://dx.doi.org/10.3816/CCC.2004.n.009

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42. http://dx.doi.org/10.1056/NEJMoa032691

Ardavanis A, Kountourakis P, Mantzaris I, Malliou S, Doufexis D, Sykoutri D, et al. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated active and convenient regimen. Anticancer Res 2008; 28: 3087-92.

Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, et al. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. Clin Colorectal Cancer 2008; 7: 390-7. http://dx.doi.org/10.3816/CCC.2008.n.052

Peters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-13. http://dx.doi.org/10.1200/JCO.2009.27.6055

Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, et al. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Med Oncol 2010; 27: 585-91. http://dx.doi.org/10.1007/s12032-009-9253-5

García-Alfonso P, Muñoz-Martín AJ, Alvarez-Suarez S, Jerez-Gilarranz Y, Riesco-Martinez M, Khosravi P, et al. Bevacizumab incombination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastastic colorectal cancer. Br J Cancer 2010; 103: 1524-8. http://dx.doi.org/10.1038/sj.bjc.6605907

Downloads

Published

2013-08-28

How to Cite

Antonieta Salud, Vicente Alonso, Pilar Escudero, Miguel Burillo, Cristina Martín, Fernando Rivera, Alfonso Yubero, Carlos García-Girón, & Alberto Muñoz. (2013). Phase II Study of Irinotecan in Combination with Capecitabine on a 3-Weekly Schedule as First-Line Chemotherapy for Patients with Metastatic or Locally Advanced Colorectal Cancer. Journal of Analytical Oncology, 2(3),  151–159. https://doi.org/10.6000/1927-7229.2013.02.03.4

Issue

Section

Articles

Similar Articles

You may also start an advanced similarity search for this article.